文献速递耳科与耳神经头颈外科小儿耳鼻咽喉

耳毒性综述:越来越多的非铂类化疗和免疫治疗药物

Ototoxicity Review: A Growing Number of Non-Platinum-Based Chemo- and Immunotherapies.
PubMed 文献 · Otolaryngol Head Neck Surg · 2023-02-05

本综述遵循PRISMA指南,检索PubMed、Embase和Web of Science数据库中关于非铂类化疗和免疫治疗药物耳毒性的已发表报告,纳入成人和儿童患者,排除含铂类药物的治疗。共发现54篇报告(39篇病例报告和15篇队列研究),记录7种药物/联合治疗的耳毒性,其中37篇(69%)发表于2005年之后;56例中21例(38%)无听力恢复记录;治疗前听力图检查不常见(54项研究中19项,35%)。作者认为耳毒性非铂类药物不断增多,建议制定标准化耳毒性监测方案。

要点

  • 非铂类化疗和免疫治疗药物耳毒性报告共54篇,涉及7种药物/联合治疗。
  • 37篇(69%)报告发表于2005年之后,提示耳毒性问题日益突出。
  • 56例中21例(38%)无听力恢复记录,治疗前听力图检查仅19/54项研究(35%)。

核心结论

  • 非铂类化疗和免疫治疗药物的耳毒性是一个不断演变的问题,涉及药物种类不断增加且机制多样。
  • 作者认为耳鼻咽喉科医生需要优先关注这些药物,并建议制定标准化耳毒性监测方案以便及时实施适当的管理选择。

研究设计与样本

  • 系统综述,遵循PRISMA指南,检索PubMed、Embase和Web of Science数据库。
  • 纳入标准为报告非铂类化疗和免疫治疗药物耳毒性的成人及儿童患者研究,排除使用任何铂类药物的治疗。

主要发现

  • 共54篇报告(39篇病例报告和15篇队列研究)记录了7种药物/联合治疗的耳毒性。
  • 37篇报告(69%)发表于2005年之后。
  • 56例中21例(38%)无听力恢复记录。
  • 治疗前听力图检查不常见,54项研究中仅19项(35%)有记录。

临床怎么用

  • 作者认为耳鼻咽喉科医生需要优先关注这些非铂类耳毒性药物。
  • 作者建议制定标准化耳毒性监测方案,以便及时实施适当的管理选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To raise awareness of the growing list of non-platinum-based chemo- and immunotherapeutic agents that have been associated with ototoxicity and to introduce the possible mechanism of ototoxicity of these agents. DATA SOURCES: PubMed, Embase, and Web of Science. REVIEW METHODS: A systematic review was performed following the PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-analyses). PubMed, Embase, and Web of Science databases were searched for published reports of ototoxicity from non-platinum-based chemo- and immunotherapeutic agents in adult and pediatric patients. Therapies that utilized any platinum-based agent were excluded. CONCLUSIONS: Ototoxicity from non-platinum-based chemo- and immunotherapies is an evolving problem. There were 54 reports-39 case reports and 15 cohort studies-documenting ototoxicity from 7 agents/combination therapies. Of these reports, 37 (69%) were published within the last 15 years (after 2005). No recovery of hearing was documented in 21 of 56 cases (38%). Pretreatment audiograms were uncommon (19/54 studies, 35%), despite documented ototoxic associations. IMPLICATIONS FOR PRACTICE: There is a growing number of novel, ototoxic, non-platinum-based chemo- and immunotherapeutic agents with various potential mechanisms of action. Otolaryngologists will need to prioritize awareness of these agents. This growing list of agents, many of which have reversible effects, suggest a need for standardized ototoxicity monitor protocols so that appropriate and timely management options can be implemented.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Naples JG, Rice-Narusch W, Watson NW, et al. Ototoxicity Review: A Growing Number of Non-Platinum-Based Chemo- and Immunotherapies. Otolaryngol Head Neck Surg. 2023. PMID: 35439087. doi:10.1177/01945998221094457

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。